Strong Tower Advisory Services Buys 3,168 Shares of Solventum Co. (NYSE:SOLV)

Strong Tower Advisory Services grew its stake in Solventum Co. (NYSE:SOLV) by 7.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 45,893 shares of the company’s stock after buying an additional 3,168 shares during the period. Solventum comprises approximately 0.8% of Strong Tower Advisory Services’ holdings, making the stock its 27th biggest position. Strong Tower Advisory Services’ holdings in Solventum were worth $3,032,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in SOLV. Merit Financial Group LLC purchased a new stake in shares of Solventum in the fourth quarter worth $235,000. Wedge Capital Management L L P NC raised its holdings in Solventum by 7.3% during the fourth quarter. Wedge Capital Management L L P NC now owns 75,283 shares of the company’s stock valued at $4,973,000 after acquiring an additional 5,094 shares during the period. Thurston Springer Miller Herd & Titak Inc. boosted its stake in shares of Solventum by 69.7% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 891 shares of the company’s stock worth $59,000 after acquiring an additional 366 shares during the period. Oak Thistle LLC purchased a new position in Solventum in the 4th quarter worth approximately $512,000. Finally, Czech National Bank boosted its position in shares of Solventum by 6.5% during the fourth quarter. Czech National Bank now owns 29,966 shares of the company’s stock worth $1,980,000 after acquiring an additional 1,820 shares during the last quarter.

Solventum Price Performance

Shares of Solventum stock opened at $73.60 on Monday. The firm’s 50-day moving average is $69.12 and its two-hundred day moving average is $65.59. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Wall Street Analyst Weigh In

Several research firms have commented on SOLV. Mizuho started coverage on shares of Solventum in a report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price objective for the company. Stifel Nicolaus initiated coverage on Solventum in a research note on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price objective on the stock. Wolfe Research started coverage on Solventum in a research report on Thursday, September 26th. They set a “peer perform” rating for the company. Piper Sandler lifted their price objective on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. Finally, Morgan Stanley lifted their price target on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $68.29.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.